112 related articles for article (PubMed ID: 16343178)
1. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer.
Ehlen TG; Hoskins PJ; Miller D; Whiteside TL; Nicodemus CF; Schultes BC; Swenerton KD
Int J Gynecol Cancer; 2005; 15(6):1023-34. PubMed ID: 16343178
[TBL] [Abstract][Full Text] [Related]
2. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients.
Gordon AN; Schultes BC; Gallion H; Edwards R; Whiteside TL; Cermak JM; Nicodemus CF
Gynecol Oncol; 2004 Aug; 94(2):340-51. PubMed ID: 15297171
[TBL] [Abstract][Full Text] [Related]
3. Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13.
Drugs R D; 2006; 7(6):379-83. PubMed ID: 17073521
[TBL] [Abstract][Full Text] [Related]
4. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer.
Berek JS; Taylor PT; Gordon A; Cunningham MJ; Finkler N; Orr J; Rivkin S; Schultes BC; Whiteside TL; Nicodemus CF
J Clin Oncol; 2004 Sep; 22(17):3507-16. PubMed ID: 15337799
[TBL] [Abstract][Full Text] [Related]
5. Oregovomab: an investigational agent for the treatment of advanced ovarian cancer.
Pietragalla A; Duranti S; Daniele G; Nero C; Ciccarone F; Lorusso D; Fagotti A; Scambia G
Expert Opin Investig Drugs; 2021 Feb; 30(2):103-110. PubMed ID: 33423551
[No Abstract] [Full Text] [Related]
6. Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab.
Berek JS
Expert Opin Biol Ther; 2004 Jul; 4(7):1159-65. PubMed ID: 15268682
[TBL] [Abstract][Full Text] [Related]
7. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer.
Berek J; Taylor P; McGuire W; Smith LM; Schultes B; Nicodemus CF
J Clin Oncol; 2009 Jan; 27(3):418-25. PubMed ID: 19075271
[TBL] [Abstract][Full Text] [Related]
8. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.
Braly P; Nicodemus CF; Chu C; Collins Y; Edwards R; Gordon A; McGuire W; Schoonmaker C; Whiteside T; Smith LM; Method M
J Immunother; 2009 Jan; 32(1):54-65. PubMed ID: 19307994
[TBL] [Abstract][Full Text] [Related]
9. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
Azad NS; Annunziata CM; Steinberg SM; Minasian L; Premkumar A; Chow C; Kotz HL; Kohn EC
Cancer; 2008 Apr; 112(8):1726-32. PubMed ID: 18300236
[TBL] [Abstract][Full Text] [Related]
10. Front-line chemoimmunotherapy for treating epithelial ovarian cancer: Part II promising results of phase 2 study of paclitaxel-carboplatin-oregovomab regimen.
Yang ST; Chang WH; Chou FW; Liu HH; Lee WL; Wang PH
Taiwan J Obstet Gynecol; 2024 Jan; 63(1):10-16. PubMed ID: 38216242
[TBL] [Abstract][Full Text] [Related]
11. CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer.
Berek JS; Taylor PT; Nicodemus CF
J Immunother; 2008; 31(2):207-14. PubMed ID: 18481390
[TBL] [Abstract][Full Text] [Related]
12. Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer.
Möbus VJ; Baum RP; Bolle M; Kreienberg R; Noujaim AA; Schultes BC; Nicodemus CF
Am J Obstet Gynecol; 2003 Jul; 189(1):28-36. PubMed ID: 12861134
[TBL] [Abstract][Full Text] [Related]
13. The antibody-based CA125-targeted maintenance therapy for the epithelial ovarian cancer: a meta-analysis.
Mei L; Hou Q; Fang F; Wang H
Eur J Gynaecol Oncol; 2016 Aug; 37(4):455-460. PubMed ID: 29894066
[TBL] [Abstract][Full Text] [Related]
14. Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial.
Buzzonetti A; Fossati M; Catzola V; Scambia G; Fattorossi A; Battaglia A
Cancer Immunol Immunother; 2014 Oct; 63(10):1037-45. PubMed ID: 24952307
[TBL] [Abstract][Full Text] [Related]
15. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
16. Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients.
Battaglia A; Buzzonetti A; Fossati M; Scambia G; Fattorossi A; Madiyalakan MR; Mahnke YD; Nicodemus C
Cancer Immunol Immunother; 2020 Mar; 69(3):383-397. PubMed ID: 31897661
[TBL] [Abstract][Full Text] [Related]
17. Identification of Anti-CA125 Antibody Responses in Ovarian Cancer Patients by a Novel Deep Sequence-Coupled Biopanning Platform.
Frietze KM; Roden RB; Lee JH; Shi Y; Peabody DS; Chackerian B
Cancer Immunol Res; 2016 Feb; 4(2):157-64. PubMed ID: 26589767
[TBL] [Abstract][Full Text] [Related]
18. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
19. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR.
Pfisterer J; du Bois A; Sehouli J; Loibl S; Reinartz S; Reuss A; Canzler U; Belau A; Jackisch C; Kimmig R; Wollschlaeger K; Heilmann V; Hilpert F
Ann Oncol; 2006 Oct; 17(10):1568-77. PubMed ID: 17005631
[TBL] [Abstract][Full Text] [Related]
20. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo.
Noujaim AA; Schultes BC; Baum RP; Madiyalakan R
Cancer Biother Radiopharm; 2001 Jun; 16(3):187-203. PubMed ID: 11471484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]